FN2 Earnings Intelligence
Alnylam Pharmaceuticals, Inc. income statement (quarterly)
Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 | 12/30/2026 est. | 3/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $1,113.7 | $1,490.2 | $1,710.8 | $1,708.3 | $1,754.3 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $773.7 | $1,249 | $1,167.2 | $1,290.9 | $1,458.1 | $1,571.3 | $1,604 |
| % Growth | - | - | - | - | - | - | 37.4% |
| Gross Profit | $631.7 | $1,051.8 | $959.7 | $992.7 | $1,096.3 | - | - |
| % Margin | 81.6% | 84.2% | 82.2% | 76.9% | 75.2% | - | - |
| EBITDA | - | - | - | - | - | - | - |
| % Margin | - | - | - | - | - | - | - |
| Net Income | -$66.3 | $251.1 | $206 | $164.5 | $2,167.3 | - | - |
| % Margin | -8.6% | 20.1% | 17.6% | 12.7% | 148.6% | - | - |
| Diluted EPS | -$0.51 | $1.84 | $1.51 | $1.21 | $15.72 | $2.05 | $2.04 |
| % Growth | - | - | - | - | - | - | 35.2% |
| Operating Cash Flow | - | - | $70.5 | - | - | - | - |
| CapEx | - | - | $21.8 | - | - | - | - |
| Free Cash Flow | - | - | $48.7 | - | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 | 12/30/2026 est. | 3/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $773.7 | $1,249 | $1,167.2 | $1,290.9 | $1,458.1 | $1,571.3 | $1,604 |
| Gross Profit | $631.7 | $1,051.8 | $959.7 | $992.7 | $1,096.3 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Net Income | -$66.3 | $251.1 | $206 | $164.5 | $2,167.3 | - | - |
| Diluted EPS | -$0.51 | $1.84 | $1.51 | $1.21 | $15.72 | $2.05 | $2.04 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,113.7 | $1,490.2 | $1,710.8 | $1,708.3 | $1,754.3 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | $646 | $648.5 | $649.8 | $651.1 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $70.5 | - | - |
| Capital Expenditure | - | - | $21.8 | - | - |
| Free Cash Flow | - | - | $48.7 | - | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 81.6% | 84.2% | 82.2% | 76.9% | 75.2% |
| EBITDA Margin | - | - | - | - | - |
| Net Margin | -8.6% | 20.1% | 17.6% | 12.7% | 148.6% |
| FCF Margin | - | - | 4.2% | - | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the ALNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.